Apolipoprotein B Gene Polymorphisms and Dyslipidemia in HIV Infected Adult Zimbabweans

Vitaris Kodogo¹, Danai Tavonga Zhou¹²*, Olav Oektedalen³, Kerina Duri¹, Babill Stray-Pedersen⁵ and Exnevia Gomo¹

¹Department of Medical Laboratory Sciences, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe
²Institute of Clinical Medicine, Oslo University Hospital, Oslo, Norway
³Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway
⁴Department of Immunology, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe
⁵Institute of Clinical Medicine, University in Oslo, and Womens Clinic, Oslo University Hospital, Oslo, Norway

Received: June 25, 2016 Revised: September 01, 2016 Accepted: September 02, 2016

Abstract:

Background:
Dyslipidemia does not occur in all HIV-infected or antiretroviral therapy-experienced patients suggesting role of host genetic factors but there is paucity of data on association between dyslipidemia and gene polymorphisms in Zimbabwe.

Objective:
To determine association of lipoprotein levels and apolipoprotein B polymorphisms in HIV-infected adults.

Method:
Demographic data were collected from 103 consenting patients; lipoprotein levels were determined and blood samples were successfully genotyped for both apolipoprotein B 2488C>T Xba1 and apolipoprotein B 4154G>A p.Gln4154Lys EcoR1 polymorphisms by real time polymerase chain reaction.

Results:
Mean age of genotyped patients was 40.3 ± 10.1 years, 68% were female; prevalence of dyslipidemia was 67.4%. Of 103 samples genotyped for apolipoprotein B Xba1 polymorphism, 76 (74%) were homozygous C/C, 24 (23%) were heterozygous C/T and only three (3%) were homozygous T/T. Apolipoprotein B EcoR1 polymorphism showed little variability, one participant had rare genotype A/A, 68.3% had wild type genotype G/G.

Conclusion:
Observed frequencies of apolipoprotein B Xba1 and EcoR1 polymorphisms matched other African studies. In spite of low numbers of rare variants, there was positive association between both total cholesterol and high density lipoprotein with ECoR1 wild type G/G genotype, suggesting that EcoR1 4154 G allele could be more protective against coronary heart disease than EcoR1 4154 A allele. There is need for further research at population level to confirm whether apolipoprotein B ECoR1 genotyping is useful for predicting risk of dyslipidemia in HIV patients in our setting.

Keywords: APOB, ART, CHD, Dyslipidemia, EcoR1, HIV, Lipoproteins, Xba1.

* Address correspondence to this author at the Department of Medical Laboratory Sciences, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe; Tel: +263 4 791630-9; Mobile: +263 772 566 214; E-mail: d.t.zhou@medisin.uio.no
INTRODUCTION

Since the introduction of antiretroviral therapy (ART), quality of life of people living with human immunodeficiency virus (PLWHIV) has remarkably improved, not to mention the considerably reduced morbidity and mortality associated with HIV/AIDS infection [1]. Despite the clinical benefits, long term ART use is associated with a complex spectrum of unwanted metabolic effects such as lipodystrophy, insulin resistance, and dyslipidemia [2 - 4]. Dyslipidemia is a disorder of lipoprotein metabolism including lipoprotein overproduction and deficiency and is a major risk factor for coronary heart disease (CHD) [5, 6]. Lipoproteins contain triglycerides, phospholipids, cholesterol and amphipathic proteins called apolipoprotein and the four major types of lipoproteins are chylomicrons, very low density lipoprotein (VLDL), low density lipoprotein (LDL), and high density lipoprotein (HDL) [7]. Earlier studies in Zimbabwe in the era before HIV and ART showed that ranges for lipoproteins, apolipoprotein B (ApoB), and triglycerides in healthy populations and diabetic patients, respectively were lower than those found in European populations [8, 9]. This suggested low prevalence of coronary heart disease (CHD) in Zimbabwean Africans. Similar findings were reported in Nigeria in the same pre-HIV era [10].

However, the current situation contradicts this perception across all groups of people in Africa as high prevalence comparable to Caucasians is being reported, due to urbanization and westernized lifestyle and the advent of HIV in most African countries [11]. Prevalence of dyslipidemia is reportedly higher in PLWHIV due to the effect of HIV and ART [12 - 15]. Concerns of increased incidence of CHD presenting as myocardial infarction in PLWHIV on antiretroviral (ARV) drugs have been confirmed in several studies [3, 16, 17]. For example, a study of young children in South Africa confirmed the adverse effect of HIV infection and ART on lipoprotein metabolism [12]. The severity of the dyslipidemia and the typical pattern of the lipid profile differs between and within the classes of antiretroviral (ARV) agents [3, 18, 19]. Several other studies in Sub-Saharan Africa suggest that the duration on ART also contributes to the severity of dyslipidemia [14, 17, 20].

In fact, there are variations in dyslipidemia even in individuals with comparable ART, demographic, immunologic, and virological characteristics [21]. This suggests that host genetic factors have a significant influence on the incidence of dyslipidemia [21, 22]. Genetic variation has been shown to account for about 43-83% of the variability of plasma lipoprotein levels in a normal healthy population [23]. Several single nucleotide polymorphisms (SNPs) associated with blood lipoprotein concentrations have been identified through genome wide association studies (GWAS) [21, 24]. Since levels of LDL predict risk of atherosclerotic CHD while ApoB is a major ligand of LDL for uptake by cell-surface receptors, the apolipoprotein B (APOB) gene was one of the candidate genes of interest in GWAS of dyslipidemia [22, 25 - 28]. Over ten polymorphisms within or flanking the APOB gene have been detected and two of the most extensively studied polymorphisms of the APOB gene are Xba1 (Pubmed ID: rs693) and EcoR1 (Pubmed ID: rs1042031) [29].

The Xba1 polymorphism arises due to a single base variation in exon 26 (at 2488th position ACC→ACT) of the APOB gene that does not lead to change in amino acid sequence [30, 31]. This base change creates a cutting site for the restriction endonuclease Xba1 and the polymorphism is known as APOB 2488C>T Xba1 polymorphism (-7673C>T) [31]. The Xba1 polymorphism has been associated with inter-individual variability of lipoprotein levels in several populations [7, 28, 32 - 34]. However, the results are conflicting in different ethnic groups.

On the other hand, the EcoR1 restriction site exists due to a change in guanidine to adenine at exon 29 (GAA→AAA), leading to the substitution of glutamine for lysine at position 4154 in the ApoB polypeptide product (p.Gln4154Lys) [32]. This nucleotide change leads to loss of the EcoR1 restriction site and the polymorphism is known as APOB 4154G>A polymorphism (-2669G>A) [32, 33]. The APOB EcoR1 polymorphism has been reported to have a positive association with raised serum lipoprotein levels, while others reported no such association [34, 35].

There have been reports of significant differences between Senegalese and Caucasians, and between Senegalese and Mongoloids for the EcoR1 allele of the APOB gene [33], but very few studies have been conducted in Africa, and to our knowledge, none in Zimbabwe. This study was conducted to determine frequency of APOB gene EcoR1 and Xba1 SNPs followed by tests for association with dyslipidemia in HIV infected Zimbabweans.

MATERIAL AND METHODS

Study Design

This was a nested cross sectional study of a cohort of 215 HIV infected, unrelated patients attending an
opportunistic infections clinic in Harare, Zimbabwe, between March and August 2013, who were previously described [36]. Two non-fasting blood samples were collected, one in 4ml EDTA tubes and the other in 4ml plain tubes using the vacutainer method. EDTA samples were used for DNA extraction whilst serum from the plain tubes was used for lipoprotein profiling. A sub-set of 103 samples was genotyped due to limited resources in our setting.

**Ethical Clearance**

The study was ethically cleared in Zimbabwe by the Joint Research Ethics Committee (JREC) and Medical Research Council of Zimbabwe (MRCZ) and in Norway by the Research Ethics Committee (REK).

**Biochemical Measurements**

Total cholesterol (TC), high density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C) serum levels were measured by enzymatic methods using the Mindray BS 120 analyser (Nanshan, People’s Republic of China) according to the manufacturer’s protocol, as previously described [36]. Dyslipidemia was defined according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines, 2004 as the occurrence of any one of the following conditions: TC >5.17 mmol/l (>200 mg/dl), LDL-C >3.16 mmol/l (>130 mg/dl), and HDL-C <1.03 mmol/l (<40 mg/dl) for males, <1.30 mmol/l (<50 mg/dl) for females [36 - 39].

**Genotype Detection**

DNA was extracted from whole blood cells using the Qiagen Mini Extraction Kit (QIAmp®, Valencia, California, USA) as per manufacturer’s protocol. A final volume of 20µl pure DNA was obtained. Quality and purity of the extracted DNA was checked using ultra-violet visible spectrophotometry at absorbance 260nM, 280nM and 360nM. Genotyping was performed by Real Time PCR (qPCR) on the Applied Biosystems 7500 platform (Life Technologies® Corporation, Foster City, USA) using Taqman® Chemistry, (Cheshire, United Kingdom). The assay kit consists of a single, ready-to-use tube containing two sequence-specific primers for amplifying the APOB polymorphism and two allele-specific TaqMan MGB probes for detecting the alleles of the specific polymorphism of interest. Vic dye is linked to the 5’end of allele 1 probe (reporter) whilst Fam dye is linked to allele 2 probe. A non-fluorescent quencher (NFQ) at the 3’end of the probe allows the detection of the reporter dye fluorescence with greater sensitivity. Reactions were performed in MicroAmp™ 96 well optical tubes in a final volume of 25µl. The reaction conditions were pre PCR read at 60°C for 1 minute, a holding stage for 10 minutes at 95°C and cycling stage of 40 cycles (denaturation 100°C, annealing 60°C and elongation at 72°C). Allelic discrimination was performed by the Sequence Detection Software (Applied Biosystems, Foster City, California, USA).

**Statistical Analysis**

Results were expressed as mean ± standard deviation (SD) or median (interquartile range-IQR) for continuous variables and as proportions for categorical variables, respectively. Allele and genotype frequencies were determined by direct counting of alleles, whilst Fisher’s exact tests were used to determine association of APOB SNPs with dyslipidemia status.

Comparison of demographic and biochemical data was carried out using student’s t-tests for means, Kruskal-Wallis equality-of-populations rank tests for medians and Pearson’s or Fisher’s exact chi-square tests for proportions. In order to adjust for sex, age, CD4 count and viral load for significant tests, post-hoc testing was carried out using multivariate regression analysis.

Chi-square analysis was used to test for deviations in genotype frequencies from the Hardy-Weinberg equilibrium (HWE) using web tool [40]. Linkage disequilibrium between rs693 and rs1042030 were evaluated with the correlation of alleles test (r2) and were considered in disequilibrium when r2≥0.33 using SHesis [41].

**RESULTS**

**Demographic and Biochemical Characteristics**

Demographic characteristics of participants by dyslipidemia status are shown in Table I. Twenty-seven (26.1%) of participants were males, frequency of dyslipidemia, as defined in the Methods section, was 70% and there was no difference in any independent variables including age, sex, ART experience, CD4 count and viral load when patients were compared by dyslipidemia status. The most prevalent type of dyslipidemia was HDL-C deficiency followed by
excess LDL-C and excess TC respectively. There was no difference in frequency of HDL-C deficiency, excess LDL-C and excess TC for those aged >35 and <35 years, respectively and when patients were stratified by sex (Table 2).

Table 1. Demographics of genotyped patients (N=103).

| Characteristics          | Non-dyslipidemic (n=31) | Dyslipidemic (n=72) | P value |
|--------------------------|-------------------------|---------------------|---------|
| Age in years (mean ± SD) | 41.8 (10.0)             | 43.0 (9.4)          | 0.5708* |
| Male n (%)               | 7 (25.9)                | 20 (74.1)           | 0.3650* |
| Female n (%)             | 24 (81.4)               | 52 (68.4)           |         |
| ART naïve n (%)          | 2 (6.4)                 | 9 (18.2)            | 0.3750* |
| ART experienced n (%)    | 29 (93.6)               | 63 (81.8)           |         |
| Years Since Diagnosis    | 4 (3-8)                 | 5 (2-8)             | 0.5772* |
| Years Since ART started  | 3 (2-7)                 | 3 (1-6)             | 0.6810* |
| CD4 count (cells per mm³) | 491 (299-590)           | 470 (303-661)       |         |
| Viral Load (copies per mm³) | 37 (20-58)              | 37 (20-58)          | 0.8760* |
| Log₁₀ Viral Load         | 1.6 (1.3-1.8)           | 1.6 (1.3-1.7)       | 0.7380* |

SD=standard deviation, IQR=interquartile range, ART=antiretroviral therapy, CD4=cluster of differentiation 4, P= from student’s t-tests, P* from Pearson chi-squared tests, P§ from Kruskal-Wallis equality-of-populations rank median tests.

Table 2. Frequencies of dyslipidemia in genotyped patients.

| Characteristic          | All (N=103) | Males (n=27) | Females (n=76) | P** | >35years (n=20) | <35years (n=83) | P*** |
|-------------------------|-------------|--------------|----------------|-----|----------------|----------------|-----|
| Non-dyslipidemic n (%)  | 31 (30)     | 6 (23)       | 25 (33)        | 0.344 | 4 (22)       | 27 (32)       | 0.458 |
| Dyslipidemic n (%)      | 72 (70)     | 21 (77)      | 51 (67)        | 0.776 | 16 (78)      | 56 (68)       |         |
| Normal HDL-C n (%)      | 43 (42)     | 11 (40)      | 32 (42)        | 0.507 | 16 (78)      | 56 (68)       |         |
| HDL-C deficient n (%)   | 60 (58)     | 16 (60)      | 44 (58)        | 0.507 | 16 (78)      | 56 (68)       |         |
| Normal LDL-C n (%)      | 76 (74)     | 19 (70)      | 57 (75)        | 0.736 | 16 (78)      | 56 (68)       |         |
| LDL-C excess n (%)      | 27 (26)     | 8 (30)       | 19 (25)        | 0.083 | 20 (100)     | 75 (90)       | 0.249 |
| Normal TC n (%)         | 95 (92)     | 27 (100)     | 68 (89)        | 0.083 | 20 (100)     | 75 (90)       |         |
| TC excess n (%)         | 8 (8)       | 0 (0)        | 8 (11)         | 0.000 | 0 (0)        | 8 (10)        |         |

P-values from Pearson’s chi-squared tests after stratifying by gender (P**) and age (P***), TC=total cholesterol, HDL-C=high density lipoprotein cholesterol, LDL-C=low density lipoprotein cholesterol, Dyslipidemic denotes presence of at least one NCEP ATP III characteristics of dyslipidemia (elevated TC> 5.2mmol/L, depressed HDL-C< 1.1mmol/L, elevated LDL-C>3.2mmol/L, elevated TC/HDL-C ratio>4.5)

Genotypic Characteristics

The genotype distributions of the two SNPs conformed to the Hardy-Weinberg equilibrium (HWE) (genotype frequencies appear in Table 3) and the two loci are in linkage disequilibrium. Seventy-six (74%) were homozygous 2488 C/C, 24 (23%) were heterozygous 2488 C/T and only three (3%) were homozygous 2488 T/T (Table 3). Seventy (68%) were homozygous wild type: 4154 G/G, 32 (31%) were heterozygous: 4154 G/A and only one patient (1%) had the homozygous mutant genotype: 4154 A/A (Table 3). No significant association was observed when genotypes were stratified by gender (Table 3).

Frequency of the 2488 C/C genotype was slightly lower (72.2%) in dyslipidemic patients compared to non-dyslipidemic patients (77.4%), but there was no statistically significant association between APOB 2488 XbaI and dyslipidemia status (Table 3). APOB minor (2488 T) allele had a frequency of 21% in the population studied and no significant association was observed between dyslipidemia and the APOB minor allele, P>0.05 (Table 3).

APOB EcoR1 polymorphism had only one patient with minor genotype 4154 A/A, while frequency of the heterozygous genotype 4154 G/A was slightly higher in non dyslipidemic (38.7%) than in dyslipidemic group (28.0%), though no significant association was observed, P=0.675. Table 3 shows the allelic frequency and distribution amongst patients. Frequency of the A allele was 15% and there was no association between the APOB EcoR1 minor allele (4154 A) and dyslipidemia status (P=0.675).

Table 4 shows median values for metabolic variables according to different genotypes; values were compared using multivariate analysis and Kruskal-Wallis equality-of-populations rank median tests. HDL-C levels were marginally
higher (P=0.056) in patients with the 4154 G/G genotype than the genotypes of 4154 A/A and 4154 G/A, respectively. One patient had the rare variant 4154 A/A and was subsequently dropped from statistical analysis, whilst three patients had the rare variant 2488 T/T and were also subsequently dropped. Hence, results for comparisons of median lipoprotein levels reported in Table 4 were based on comparison between two groups consisting wild type 4154 G/G and heterozygotes (4154 G/A) or wild type 2488 C/C against 2488 C/T. The difference in median levels of TC and HDL-C was more apparent for 4154 G/G versus 4154 G/A (P=0.0049 and P=0.0106, respectively), but there was still no difference in levels of LDL-C and TC/HDL-C ratio, (Table 4). The association of APOB EcoR1 SNPs with TC (P=0.012) and HDL-C (P=0.011) remained when adjusted by age, gender, CD4 count and viral load (Table 5). There was no statistically significant association between all lipoprotein levels and Xba1 genotype variants (2488 C/C against 2488 C/T) p<0.05, (Table 4).

Table 3. Distribution of APOB polymorphisms by gender and dyslipidemia status.

| Genotypes | Male (N=27) | Female (N=76) | P value |
|-----------|-------------|---------------|--------|
| Distribution of 2488 XbaI genotype and allele frequencies by gender |
| Genotypic frequency | | | |
| C/C (n=76) | 23 (86.2) | 53 (69.5) | 0.232 |
| C/T (n=24) | 3 (10.3) | 21 (28.1) | |
| T/T (n=3) | 1 (3.5) | 2 (2.4) | |
| Allelic frequency | | | |
| C (0.86) | 0.911 | 0.83 | |
| T (0.14) | 0.09 | 0.17 | |
| Genotypes | Male | Female | P value |
| Distribution of 4154 EcoRI genotype and allele frequencies by gender |
| Genotypic frequency | | | |
| G/G (n=70) | 18 (67.0) | 52 (68.4) | 0.937 |
| G/A (n=32) | 9 (33.0) | 23 (30.2) | |
| A/A (n=1) | 0 | 1 (1.4) | |
| Allelic frequency | | | |
| G (0.84) | 0.84 | 0.84 | 0.910 |
| A (0.16) | 0.16 | 0.16 | |
| Distribution of 2488 XbaI genotype and allele frequencies by dyslipidemia status |
| Genotypic frequency | | | |
| Genotype | Dyslipidemic n(%) | Non-dyslipidemic n(%) | P value |
| C/C (n=76) | 52 (72.2) | 24 (77.4) | 0.653 |
| C/T (n=24) | 19 (26.4) | 5 (16.1) | |
| T/T (n=3) | 1 (1.4) | 2 (6.5) | |
| Allelic frequency | | | |
| C | 0.85 | 0.86 | 0.845 |
| T | 0.15 | 0.14 | |
| Distribution of 4154 EcoRI genotypes and allele frequencies by dyslipidemia status |
| Genotypic frequency | | | |
| Genotype | Dyslipidemic n (%) | Non-dyslipidemic n (%) | P value |
| G/G (n=70) | 51 (70.8) | 19 (61.3) | 0.675 |
| G/A (n=32) | 20 (28.0) | 12 (38.7) | |
| A/A (n=1) | 1 (1.2) | 0 | |
| Allelic frequencies | | | |
| G | 0.85 | 0.81 | 0.699 |
| A | 0.15 | 0.19 | |

Genotype frequencies presented as numbers (%), G and A are alleles at the APOB EcoR1 locus, C and T are alleles at APOB XbaI locus, *Genotype frequencies conformed to the Hardy-Weinberg equilibrium (q=1-p)

DISCUSSION

Many studies have been performed to date to investigate association between APOB gene polymorphisms and lipoprotein levels in other parts of the world [42, 43]. However, this is the first research showing both allelic frequencies of APOB XbaI and EcoR1 SNPs in a Zimbabwean HIV cohort and association between APOB EcoR1 gene
variants with TC and HDL-C levels; with higher levels of TC and HDL-C in 4154 G/G carriers after adjusting for age, gender, CD4 count and viral load (P<0.05). However no association was found between APOB Xba1 gene variants and lipoprotein levels, which confirm previous observations, that 2488T allele is not a risk factor for dyslipidemia.

Table 4. Metabolic variables according to polymorphisms.

| Lipid Profiles | TC/mmol/L | HDL/mmol/L | LDL/mmol/L | TC/HDL ratio |
|----------------|-----------|------------|------------|--------------|
| **Single nucleotide Polymorphisms** |           |            |            |              |
| APOB EcoR1 | | | | |
| GG n=70 | 4.7 (3.7-5.2) | 1.3 (1.0-1.6) | 2.6 (2.1-3.5) | 3.6 (2.8-4.7) |
| GA n=32 | 4.3 (4.1-5.2) | 1.1 (0.9-1.3) | 2.4 (0.9-2.8) | 3.6 (3.0-4.4) |
| P | 0.0049 | 0.0106 | 0.1041 | 0.6625 |
| APOB Xba1 | | | | |
| CC n=76 | 4.4 (3.7-5.2) | 1.2 (1.0-1.5) | 2.6 (2.1-3.4) | 3.6 (3.0-4.5) |
| CT n=24 | 4.3 (4.1-5.2) | 1.2 (1.0-1.5) | 2.4 (2.1-3.3) | 4.2 (3.0-4.7) |
| P | 0.5248 | 0.8405 | 0.4210 | 0.3172 |

*p* values calculated using Kruskal-Wallis equality-of-populations rank median tests in Stata, Rare variants dropped from analysis, Genotypes: EcoR1 (GG, GA, AA); Xba1 (CC, CT, TT)

Table 5. Metabolic variables according to APOB EcoR1 SNPs.

| Lipid Profiles | TC/mmol/L | HDL/mmol/L |
|----------------|-----------|------------|
| GG n=70 | 4.7 (3.7-5.2) | 1.3 (1.0-1.6) |
| GA n=32 | 4.3 (4.1-5.2) | 1.1 (0.9-1.5) |
| *P* (adjusted) | 0.012 | 0.011 |

*p* values calculated using multivariate regression analysis, to adjust for age, sex, CD4 count and viral load.

Frequency of the EcoR1 4154 G allele is high in our population compared to other populations. In agreement with our study, a study conducted in India [30] reported only the presence of 4154 G/G and 4154 G/A genotypes in their population while a study in Senegalese had slightly higher frequency of the 4154 A/A genotype *i.e.* 0.08 [33]. Likewise, the frequency of the EcoR1 rare genotype 4154 A/A reported in Caucasians (0.24) [33] is higher than that reported in Zimbabweans, as well as in other African studies. The Xba1 2488 T/T genotype polymorphism is rare in our population. Its frequency (0.03) is slightly lower than that reported from a study in Senegalese HIV patients (0.08-0.16) whilst a study in Nigeria reported a similar frequency which is comparable to results from Mongoloids where frequencies ranged from 0.01 to 0.07 [28, 33].

In studies that involved both Africans and Mongoloids, no association of the Xba1 2488 T allele and plasma lipoproteins were observed [7, 28, 33]. However, association of the 4154 A allele to plasma lipoproteins has been reported in many studies involving HIV positive Caucasians, though lack of association was reported in HIV positive Senegalese and Chinese populations [21]. Unlike Zimbabwean individuals, Caucasian individuals have higher frequencies of the 2488 T allele, reported allele frequencies range between 0.33 and 0.61 in Caucasians [34].

Patients with the homozygous 4154 G/G genotype showed trend toward more favorable lipoprotein values (higher HDL-C) and could be more protected against CHD. Of note, a high fraction of the patients carry this genotype in the population studied. An earlier study conducted to examine the role of APOB gene polymorphisms in responsiveness of plasma lipoproteins to diet in 44 healthy participants in Finland [44] observed that a high-fat diet induced a larger increase in plasma LDL-C in subjects with the 4154 A/A genotype than in those with the 4154 G/A or 4154 G/G genotype. Hence 4154 G/G carriers are protected against CHD for slightly different reasons in Finns compared to the Zimbabwean cohort reported here.

Finally, it is very difficult to explain the association between APOB gene variation and HDL-C levels reported here because genetic variations of enzymes, receptors, and apoB a protein essential to LDL-C metabolism, are partially involved in the regulation of serum LDL-C and TC but not HDL-C [45]. It is however important to remember that serum lipids have a multi-factorial etiology that is determined by a large number of environmental and genetic factors and detailed mechanisms of their interactions are not well known. HIV infection in patients has prior been associated
with a highly atherogenic lipid profile with increased levels of TC and LDL-C accompanied by decreased levels of HDL-C [45]. Thus results of this study should be received with caution and may need further enquiry.

LIMITATIONS OF STUDY

Failure to get sufficient numbers of the mutant alleles, inadequate choice of genetic variant, phenotype being affected by many variants at several genes, use of single markers instead of haplotypes and gene-environment interactions might have contributed to lack of associations observed in our study for Xba1 2488 variants [46]. Study results and conclusions for the EcoR1 variants in the current study were also severely weakened by the small sample size, scarcity of investigated variants and cross-sectional nature of the study. Future population-wide longitudinal studies are warranted in this setting to strengthen the power of study and reduce type II errors. Furthermore, the inclusion of patients on different ART regimens is a difficulty inherent to many studies involving patients already receiving ART [21], hence larger population-based studies can improve the number of patients in sub-groups, a necessary step for enhancing power in any subsequent comparative analysis.

CONCLUSION

Dyslipidemia is highly prevalent in HIV patients in Zimbabwe both ART experienced and ART naives. Frequencies for TC, LDL-C excess and HDL-C deficiency were similar across gender and age lines. Observed frequencies of APOB Xba1 and EcoR1 polymorphisms matched other African studies. There was positive association between EcoR1 wild type genotype 4154 G/G with HDL-C levels which could indicate that homozygous 4154 G/G genotype carriers are more protected from CHD via increase in HDL-C.

CONFLICT OF INTEREST

The authors confirm that this article content has no conflict of interest.

ACKNOWLEDGEMENTS

We would like to express our gratitude to Letten Foundation Research Centre and the late Professor Letten Saugstad for funding the project. We are also indebted to the African Institute of Biomedical Sciences (AIBST) for providing the laboratory space for genotyping. None of this work would have been successful without the voluntary participation of Newlands Clinic patients and staff. We also want to thank the University of Zimbabwe, College of Health of Sciences, Department of Medical Laboratory Science academic, technical staff and students for their unwavering support. Last but not least, to Kudzaishe Mateveke of the University of Zimbabwe, College of Health of Sciences’ Research Support Centre for support during statistical analysis.

REFERENCES

[1] Zimbabwe National HIV and AIDS Strategic Plan. Available from: http://www.safaids.net/files/ZNASP%202006-2010.pdf. 2010.
[2] Feeney ER, Mallon PW. HIV and HAART-Associated dyslipidemia. Open Cardiovasc Med J 2011; 5: 49-63. [http://dx.doi.org/10.2174/1874192401105010049] [PMID: 21643501]
[3] Estrada V, Portilla J. Dyslipidemia related to antiretroviral therapy. AIDS Rev 2011; 13(1): 49-56. [PMID: 21412389]
[4] Dubé MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37(5): 613-27. [http://dx.doi.org/10.1086/378131] [PMID: 12942391]
[5] Manjunath CN, Rawal JR, Irani PM, Madhu K. Atherogenic dyslipidemia. Indian J Endocrinol Metab 2013; 17(6): 969-76. [http://dx.doi.org/10.4103/2230-8210.122660] [PMID: 24381869]
[6] Miller M. Dyslipidemia and cardiovascular risk: the importance of early prevention. Q J Med 2009; 102: 657-67. [http://dx.doi.org/10.1093/qjmed/hcp]
[7] Cox RA, García-Palmieri MR. Cholesterol, Triglycerides, and Associated Lipoproteins. In: Walker HK, Hall WD, Hurst JW, Eds. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd ed. Boston: Butterworths 1990.
[8] Gomu ZAR. Concentrations of lipids, lipoprotein, and apolipoproteins in serum of Zimbabwean Africans. Clin Chem 1985; 31(8): 1390-2.
[9] Makuya D, Gomo Z, Muyombwe T, Matenga JA, Hakim JG. Metabolic syndrome disorders in urban black Zimbabweans with type 2 Diabetes mellitus. Cent Afr J Med 2004; 50(3-4): 24-9. [PMID: 15409713]
[10] Kesteloot H, Oviasu VO, Obasohan AO, Olomu A, Cobbaert C, Lissens W. Serum lipid and apolipoprotein levels in a Nigerian population sample. Atherosclerosis 1989; 78(1): 33-8. [PMID: 2502993]

[11] Ogajefor OC, Onwukwe CH, Odenigbo CU. Dyslipidemia in Nigeria: prevalence and pattern. Ann Afr Med 2012; 11(4): 197-202. [PMID: 23103917]

[12] Strehlau R, Coovadia A, Abrams EJ, et al. Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy. J Acquir Immune Defic Syndr 2012; 60(4): 369-76. [PMID: 22134152]

[13] Satyajit D. Mechanism of lipid disorder in HIV infection: apolipoprotein-B kinetics, fat distribution, insulin resistance and adipocytokines in patients taking protease inhibitors or non-nucleoside reverse transcriptase inhibitors. Univ Birmingham Res Arch e-theses Repos 2010. Available from: http://etheses.bham.ac.uk/1475.

[14] Adewole OO, Eze S, Betiku Y, et al. Lipid profile in HIV/AIDS patients in Nigeria. Afr Health Sci 2010; 10(2): 144-9. [PMID: 21326966]

[15] Gomo ZA, Hakim JG, Walker SA, et al. Impact of second-line antiretroviral regimens on lipid profiles in an African setting: the DART trial sub-study. AIDS Res Ther 2014; 11(1): 32. [PMID: 25320632]

[16] Tawesos A, Addis Z, Ambachew H, Banerjee S. Prevalence of dyslipidemia among HIV-infected patients using first-line highly active antiretroviral therapy in Southern Ethiopia: a cross-sectional comparative group study. AIDS Res Ther 2012; 9(1): 31. [PMID: 21186640]

[17] Kiage JN, Heimburger DC, Nyirenda CK, Gomo ZA, Hakim JG, Walker SA, Tadewos A, Addis Z, Ambachew H, Banerjee S. Prevalence of dyslipidemia among HIV-infected patients using first-line highly active antiretroviral therapy. Lipids Health Dis 2013; 12(50): 50. [PMID: 23575345]

[18] Tungsiripat M, Aberg JA. Dyslipidemia in HIV patients. Cleve Clin J Med 2005; 72(12): 1113-20. [PMID: 16392725]

[19] Buchacz K, Weidle PJ, Moore D, et al. Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 2008; 47(3): 304-11. [PMID: 18398971]

[20] Dimodi HT, Etame LS, Nguimkeng BS, et al. Prevalence of metabolic syndrome in HIV-Infected Cameroon patients. World J AIDS 2014; 4: 85-92. [PMID: 24023696]

[21] Lazzaretti RK, Gasparotto AS, Sassi MG, et al. Genetic markers associated to dyslipidemia in HIV-infected individuals on HAART. ScientificWorldJournal 2013; 2013(155): 608415. [PMID: 24191141]

[22] Gallegos-Arreola MP, Valdez Y, Záhiga-Corona M, et al. Association between the Xba I polymorphism of APOB gene and plasma lipid level in Mexican patients with coronary artery disease. Asia Pac J Clin Nutr 2011; 20(2): 31-8. [PMID: 22057620]

[23] Rios-González BE, Luévano-Ortega KE, Saldaña-Cruz AM, González-García JR, Magaña-Torres MT. Polymorphisms of seven genes involved in lipid metabolism in an unscreened Mexican population. J Genet 2011; 90(3): e114-9. [PMID: 22232194]

[24] Nock NL, Aiswarya AL, Pillai C. Dyslipidemia: genetics and role in the metabolic syndrome. In: Kelishadi R, Ed. Dyslipidemia - From Prevention to Treatment. Intech, Croatia 2012.

[25] Contois JH, McConnell JP, Sethi AA, et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC lipoproteins and vascular diseases division working group on best practices. Clin Chem 2009; 55(3): 407-19. [PMID: 19168552]

[26] Musunuru K. Atherogenic dyslipidemia: cardiovascular risk and dietary intervention. Lipids 2010; 45(10): 907-14. [PMID: 20524075]

[27] Liu X, Wang Y, Qu H, et al. Associations of polymorphisms of rs693 and rs1042031 in apolipoprotein B gene with risk of breast cancer in Chinese. Jpn J Clin Oncol 2013; 43(4): 362-8. [PMID: 23444115]

[28] Bogari NM, Abdel-Latif AM, Hassan MA, Fawzy A, Apolipoprotein B (XbaI) allele frequencies in an Egyptian Population: impact on blood lipids. Int J Biol Med Res 2014; 5(2): 3981-7.

[29] Hong SH, Song J, Kim QJ. The haplotype analyses using multiple markers of the apolipoprotein B gene in patients with coronary artery disease. J Korean Med Sci 2001; 16(6): 719-24. [PMID: 11748351]

[30] Srivastava N, Prakash J, Srivastava A, Agarwal CG, Pant DC, Mittal B. Association of apolipoprotein B XbaI gene polymorphism and lipid profile in northern Indian obese. Indian J Hum Genet 2013; 19(1): 26-31. [PMID: 23901190]
[31] Kurzawski M, Juzyszyn Z, Modrzejewski A, et al. Apolipoprotein b (APOB) gene polymorphism in patients with gallbladder disease. Arch Med Res 2007; 38: 360e-3.

[32] Sharma R, Mahajan M, Singh B, Singh G, Singh P. Role of the APOB gene polymorphism (c.12669G>A, p.Gln4154Lys) in coronary artery disease in the Indian Punjabi population. Balkan J Med Genet 2011; 14(2): 35-40. [http://dx.doi.org/10.2478/v10034-011-0045-9] [PMID: 24052710]

[33] Chauffert M, Larghero J, Ngohou-Butum K, Cisse A, Chevenne D, Trivin F. DNA polymorphisms of apolipoprotein B in the population of Senegal. Ann Hum Genet 1997; 61(Pt 6): 525-9. [http://dx.doi.org/10.1046/j.1460-1809.1997.6106052.x] [PMID: 9543553]

[34] Zhao WY, Huang JF, Wang LY, et al. Association of the apolipoprotein B gene polymorphisms with essential hypertension in Northern Chinese Han population. Biomed Environ Sci 2007; 20(3): 260-4. [PMID: 17672218]

[35] Arnedo M, Taffé P, Sahli R, et al. Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenomics Genomics 2007; 17(9): 755-64. [http://dx.doi.org/10.1097/FPC.0b013e32814db8b7]

[36] Zhou DT, Kodogo V, Chokuona KVF, Gomo E, Oektedalen O, Stray-Pedersen B. Dyslipidemia and cardiovascular disease risk profiles of patients attending an HIV treatment clinic in Harare, Zimbabwe. HIV/AIDS (Auckl) 2015; 7: 145-55. [http://dx.doi.org/10.2147/HIV.S78523] [PMCID: PMC4435239]

[37] Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2004; 106(25): 3143-421.

[38] Zhou DT, Nehumba D, Oktedalen O, et al. Changes in lipid profiles of HIV+ adults over nine months at a Harare HIV clinic A longitudinal study, Biochem Res Int 2016; 2016: 7. [PMID: 3204818]

[39] Liu E, Armstrong C, Spiegelman D, et al. First-line antiretroviral therapy and changes in lipid levels over 3 years among HIV-Infected adults in tanzania. Clin Infect Dis 2013; 56(12): 1820-8.

[40] Rodriguez S, Gaunt TR, Day IN. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 2009; 169(4): 505-14. [http://dx.doi.org/10.1093/aje/kwp259] [PMID: 19126586]

[41] Li XL, Wu ZL, Liu ZZ, Gong YF, Zhou RY, Zheng GR. SNP identification and analysis in part of intron 2 of goat MSTN gene and variation within and among species. J Hered 2006; 97(3): 285-9. [http://dx.doi.org/10.1093/jhered/esj026] [PMID: 16624893]

[42] de Benedictis G, Rose G, Mazzei R, et al. EcoRI-RFLP of the Apo B gene: a study in a sample group from south Italy. Ann Hum Genet 1991; 55(pt2): 103-3. [PMID: 1683209]

[43] Glisic S, Savic I, Alavantice D. Apolipoprotein B gene DNA polymorphisms (EcoRI and Mspl) and serum lipid levels in the Serbian healthy population: interaction of rare alleles and smoking and cholesterol levels Genet Epidemiol 1995; 12 : 499e -508 .

[44] Armstrong C, Liu E, Okuma J, et al. Dyslipidemia in an HIV-positive, antiretroviral treatment-naive population in Dar es Salaam, Tanzania. J Acquir Immune Defic Synd 2001; 37 (2): 1441-5.

[45] Kallel A, Jemaa R, Feki M, et al. XbaI polymorphism in Tunisian population allele frequencies and relation with plasma lipid parameters. Ann Biol Clin (Paris) 2007; 65(3): 265-70. [PMID: 17502298]

[46] Ordovas JM. Pharmacogenetics of lipid diseases. Hum Genomics 2004; 1(2): 111-25. [http://dx.doi.org/10.1186/1479-7364-1-2-111] [PMID: 15601539]